Processing

Please wait...

Settings

Settings

Goto Application

1. WO2015101928 - FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS

Publication Number WO/2015/101928
Publication Date 09.07.2015
International Application No. PCT/IB2014/067408
International Filing Date 30.12.2014
IPC
A61K 31/496 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/429 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
429condensed with heterocyclic ring systems
C07D 279/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
279Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
041,3-Thiazines; Hydrogenated 1,3-thiazines
08condensed with carbocyclic rings or ring systems
CPC
C07D 277/60
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
277Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
60condensed with carbocyclic rings or ring-systems
C07D 417/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
417Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 513/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
513Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • AURIGENE DISCOVERY TECHNOLOGIES LIMITED [IN]/[IN]
Inventors
  • KOTRABASAIAH UJJINAMATADA, Ravi
  • HOSAHALLI, Subramanya
  • BEJUGAM, Mallesham
Priority Data
243/CHE/201421.01.2014IN
6203/CHE/201331.12.2013IN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS
(FR) DÉRIVÉS DE THIOPHÈNE ET DE THIAZOLE FUSIONNÉS UTILISÉS EN TANT QUE MODULATEURS GAMMA ROR
Abstract
(EN) The present invention provides fused thiophene and thiazole derivatives of formula (I), which may be therapeutically useful, more particularly as RORγ modulators; in which R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n and ring A have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in disease(s) or disorder(s) where there is an advantage in modulating RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the fused thiophene and thiazole derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
(FR) La présente invention concerne des dérivés de thiophène et de thiazole fusionnés de formule (I), qui peuvent être thérapeutiquement utiles, plus particulièrement en tant que modulateurs RORγ. Dans ladite formule, R1, R2, R3, R4, R5, R6, R7, X1, X2, L, m, n et le cycle A ont les significations décrites dans la description. L'invention porte également sur leurs sels pharmaceutiquement acceptables utiles dans le traitement et la prévention d'états pathologiques ou de troubles, et en particulier sur leur utilisation dans un ou plusieurs états pathologiques ou troubles pour lesquels il est avantageux de moduler le récepteur RORγ. L'invention concerne également la préparation de composés et de formulations pharmaceutiques comprenant au moins l'un des dérivés de thiophène et de thiazole fusionnés de formule (I), associés à un vecteur, un diluant, ou un excipient pharmaceutiquement acceptable.
Latest bibliographic data on file with the International Bureau